TABLE 3.

FDA-Approved Antiresorptive and Anabolic Therapies Used in Randomized Clinical Trials (53,54)

Drug	Name of study	No. of patients	RR% of vertebral Fx	RR% of hip Fx
Antiresorptive therapies
Calcitonin	PROOF	1,255	36	NS
Raloxifene	MORE	7,704	30–55	NS
HRT/ERT	WHI	16,608	34	34–39
Alendronate	FIT-1	2,027	47	51
Risedronate	VERT	2,458	41–49	NA
Risedronate	HIP-OP	5,445	NA	40
Ibandronate	BONE	2,946	52	NS
Zoledronic acid	HORIZON	7,765	70	41
Denosumab	FREEDOM	7,868	68	40
Anabolic therapies
Teriparatide	NCT00670501*	1,637	84	NA
Abaloparatide	ACTIVE	2,463	86	43 (NV Fx)
Romosozumab	FRAME	7,180	83	NS

^*ClinicalTrials.gov identifier.

RR = relative risk reduction; Fx = fracture; HRT/ERT = hormone replacement therapy/estrogen replacement therapy; NS = not significant; NA = not available; NV Fx = nonvertebral fracture.